Titel	Veröffentlichungsdatum	Sprache	Zitate
Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197	2014/12/01	English	3
Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product	2016/08/01	English	2
Challenging issues in assessing analytical similarity in biosimilar studies	2015/05/01	English	1
Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases	2013/01/01	English	1
A European perspective on the market accessibility of biosimilars	2012/11/01	English	1
Multidisciplinary approach to evaluating immunogenicity of biosimilars: lessons learnt and open questions based on 10 years' experience of the European Union regulatory pathway	2014/06/01	English	1
Biosimilars: an overview	2011/03/01	English	1
Rituximab and biosimilars – equivalence and reciprocity	2013/06/01	English	1
Global regulatory landscape of biosimilars: emerging and established market perspectives	2015/02/01	English	1
Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia	2012/09/01	English
Production and analysis of a biosimilar erythropoietin in Egypt	2014/05/01	English
Clinical efficacy and safety of Zarzio® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor	2014/03/01	English
Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems	2014/11/01	English
Establishing a new marketplace for biologic therapy with biosimilar agents: importance of extrapolation of data	2015/06/01	English
Clinical trials in the development of biosimilars: future considerations	2015/07/01	English
Development, safety, and efficacy of biosimilar adalimumab: the data so far	2016/01/01	English
Current and future biosimilars: potential practical applications in rheumatology	2013/08/01	English
Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia	2013/08/01	English
Clinical efficacy and safety of Tevagrastim® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor	2013/08/01	English
Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics	2011/06/01	English
Tools for the analysis and characterization of therapeutic protein species	2016/05/01	English
Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: results of MATRIX, a cross-sectional, multicenter phase 4 study	2015/09/01	English
Label-free interaction analysis as a tool to demonstrate biosimilarity of therapeutic monoclonal antibodies	2015/09/01	English
Pharmacokinetic and pharmacodynamic properties of a new biosimilar filgrastim TPI G-CSF in comparison to the marketed reference filgrastim Neupogen®: a double-blind, single-dose, two-period crossover trial	2015/11/01	English
The development and introduction of biosimilar anticoagulants – focus on enoxaparin	2012/09/01	English
Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia	2012/08/01	English
Adalimumab: a review of the reference product and biosimilars	2016/07/01	English
Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia	2013/08/01	English
Clinical efficacy and safety of biosimilar epoetin: focus on epoetin zeta	2015/09/01	English
Considerations in biosimilar insulin device development	2016/02/01	English